National
‘Don’t Ask’ repeal is priority No. 1 as Congress returns
Advocacy groups plan aggressive lobbying effort next week
A gay veterans group is planning a series of events next week to highlight the need to repeal “Don’t Ask, Don’t Tell” as the Senate could take action on the issue this month.
Servicemembers United is organizing a lobby day on Sept. 16 for gay veterans and other supporters of repeal to ask members of Congress to support passage of the fiscal year 2011 defense authorization bill and pending language that would lead to repeal of “Don’t Ask, Don’t Tell.”
Additionally, the organization is planning on the same day an event for the same-sex partners of U.S. service members. Servicemembers United will also host a gala Sept. 17 at its office to raise money for the organization.
The events come as many repeal supporters are pushing for and expecting the Senate to take up the fiscal year 2011 defense authorization bill and “Don’t Ask, Don’t Tell” this month after lawmakers return from August recess.
Michael Cole, a Human Rights Campaign spokesperson, said taking up repeal of “Don’t Ask, Don’t Tell” is the first priority for HRC when lawmakers return next week.
“We are communicating with our allies on the Hill to let them know that we’re looking for them to finish the job,” Cole said. “We feel confident that the votes are there and that it’s time that we rid our laws of this terrible policy.”
Cole said the Senate reportedly is looking at the week of Sept. 20 to take up the defense authorization bill and the “Don’t Ask, Don’t Tell” language in the legislation.
The upcoming lobby day and other events are intended to build pressure on Congress in the remaining days before the vote to move forward with repeal.
Alex Nicholson, executive director of Servicemembers United, said the idea for the upcoming lobby day came after the organization and HRC jointly organized a similar lobby day on “Don’t Ask, Don’t Tell” in May.
“It’s something that has value outside of just the lobbying,” Nicholson said. “It’s an opportunity for vets from all over the country, supporters to get together and connect to socialize, to meet, to work together, collaborate.”
Nicholson said he’s expecting around between 50 and 100 people to attend the upcoming lobby day and estimated around 75 percent of attendees would be former U.S. service members.
But Nicholson said the lobby day next week would be different from the lobby day in the spring in many respects. One major difference will be that rather than simply pushing lawmakers to repeal “Don’t Ask, Don’t Tell,” participants in the upcoming lobby day would ask members of Congress to support certain concrete actions.
“We’re focused on a different objective right now with this lobby day, which is the quality of the visits and the nuances of where the issue is right now,” Nicholson said. “We’re in a very different place right now than we were in early May and there’s some very specific procedural votes that are going to happen.”
Nicholson said the five actions that participants will ask lawmakers to take will be to:
• Oppose a motion to strike the repeal language from the defense authorization bill;
• Oppose any replacement or substitute amendment with respect to the repeal language;
• Oppose any other attempt to modify or remove the repeal language in the defense authorization bill;
• Oppose any filibuster attempt of the defense authorization bill as a whole;
• and support final passage of the defense authorization bill.
Nicholson said this approach to repeal is necessary because many members of Congress hold nuanced positions on “Don’t Ask, Don’t Tell.”
“People like Sen. Jim Webb can say, ‘I do support repeal of Don’t Ask, Don’t Tell, just not this year,’ or ‘I do support it; I’m just going to support it within an expanded certification,'” Nicholson said. “So, we want to make sure that people who are doing our work have the detailed knowledge to be able to push back on these attempts to get around to actually voting for repeal this year.”
Additionally, the upcoming lobby day will differ from the previous lobby day because different members of the Senate are being targeted.
Previously, the repeal supporters had been working to influence the Senate Armed Services Committee to adopt repeal language as part of the defense authorization bill. Now that the committee has taken action to include the language in the legislation, the focus is on the Senate as a whole.
Nicholson said the targeted senators of the upcoming lobby day are Sens. Kent Conrad (D-N.D.), Byron Dorgan (D-N.D.), Judd Gregg (R-N.H.), Tim Johnson (D-S.D.), Blanche Lincoln (D-Ark.), Mark Pryor (D-Ark.) and Mark Warner (D-Va.).
One senator that Nicholson said will get “special attention” is Senate Majority Leader Harry Reid (D-Nev.) because he’s the sole person who can ensure the defense authorization bill sees a vote this month.
Even though the Senate is the priority for repeal supporters because a vote in that chamber is imminent, Nicholson said the lobby day will also involve visits to members of the U.S. House, which has already approved the defense authorization bill with “Don’t Ask, Don’t Tell” repeal language.
“I’m a big believer in follow up and gratitude and appreciation,” Nicholson said. “And so, we’re also doing, where possible, we’re doing some visits with House staff to follow up and thank them for their support, especially for some of the members for whom it was hard to take this vote.”
Servicemembers United is the sole organizer of the upcoming lobby day and is not working with HRC to draw citizen lobbyists from across the country.
“We’ve grown to the point now where we can do something like this by ourselves, and so we decided to convene another lobby day,” Nicholson said.
Still, Nicholson said while previously Servicemembers United was able to rely on HRC to pay to bring people into D.C. from across the country, interested participants will now have to pay their own travel expenses
“They paid for a lot of tickets for people to come into town, and we don’t have that kind of money to throw down on this, so we’re obviously relying on people who are motivated and have the capacity to bring themselves here,” Nicholson said.
As the lobby day approaches, Nicholson said he’s feeling “fairly optimistic” that the Senate will pass a defense authorization bill that includes language for “Don’t Ask, Don’t Tell” repeal, provided Reid brings the legislation to the floor for a vote.
“I think chances are pretty good that we’ll get that through to fruition if Sen. Reid brings it to the floor for a vote before they recess for election season,” Nicholson said. “If he doesn’t, I don’t know what to think. I sort of throw my hands up in the air at that point at that and say, ‘Let’s wait and see,’ because anything could happen.”
On the same day as the lobby day on Capitol Hill, Servicemembers United is also hosting a forum for the same-sex partners of U.S. service members.
Nicholson said the forum is the first ever for the same-sex partners of U.S. service members and is intended to facilitate conversations among those who are in same-sex relationships with those serving in the military.
“Partners are coming to meet each other to talk, to connect, to share their stories and experiences with each other to talk about they challenges, offer advice and get to know one another,” Nicholson said.
Nicholson said the event will be small in scale and estimated about 10 to 15 people will attend.
One component of this forum will be a meeting with the partners and the Pentagon working group that is developing a plan to implement repeal of “Don’t Ask, Don’t Tell.”
Nicholson said he thinks this meeting will be similar to the meeting that repeal supporters arranged with the Pentagon working group for gay veterans in May.
“The Pentagon working group’s style with meeting with groups of people like this has been to let it be an open dialogue with some introductions and talking a little bit about their work and what they’ve been charged with,” Nicholson said.
Nicholson said he thinks that military partners would talk about their experience being the partner of a gay, lesbian or bisexual service members serving under “Don’t Ask, Don’t Tell” and advocate on their partners’ behalf.
Cynthia Smith, a Pentagon spokesperson, confirmed that members of the Pentagon working group are set to meet with the same-sex partners of U.S. service members. Still, she said she couldn’t yet identify which members of the working group would meet with the partners.
“We’re just going to discuss what impact the possible repeal would have on military readiness, unit cohesion, family readiness and recruiting and retention — the same thing we’re asking the spouses of heterosexual partners,” she said. “We understand their voice is very important and we want to hear from them as well.”
But could the same-sex partners of service members inadvertently out their partners under “Don’t Ask, Don’t Tell” during the discussion with the working group?
Smith said the working group will establish guidelines prior to the meeting warning participants not to identify their partners.
“We’re going to establish ground rules that we don’t want them to out a partner,” she said. “Obviously, we’re going to establish those ground rules up front.”
Nicholson said he doesn’t think U.S. service members would be outed by same-sex partners because they “live under the cloud of ‘Don’t Ask, Don’t Tell’ just like their active duty partners.”
“They develop the same risk-aversion instincts as active duty gay and lesbian troops and are fully capable of avoiding the inadvertent outing of their partners,” Nicholson said. “This experience won’t be an unfamiliar one for them in that sense.”
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Looking back at the 10 biggest A&E stories of 2025
Kazakh president signs anti-LGBTQ propaganda bill
Top 10 LGBTQ local news stories of 2025
The 25 greatest queer movies of the 21st century so far
How to cope when a partner gives you the silent treatment
Your guide to D.C.’s queer New Year’s Eve parties
Holiday week brings setbacks for Trump-Vance trans agenda
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
